Connect with us

Bloomberg Technology

Fauci Says Results of Gilead Virus-Drug Trial Show ‘Good News’

Apr.29 — Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, says that early results of clinical trial offered “quite good news” regarding a potential Covid-19 therapy made by Gilead Sciences Inc. He speaks at a White House meeting with President Donald Trump and Louisiana Governor John Bel Edwards.

Published

on

Apr.29 — Dr. Anthony Fauci, director of the U.S. National Institute of Allergy and Infectious Diseases, says that early results of clinical trial offered “quite good news” regarding a potential Covid-19 therapy made by Gilead Sciences Inc. He speaks at a White House meeting with President Donald Trump and Louisiana Governor John Bel Edwards.

Continue Reading
Advertisement
25 Comments

25 Comments

  1. Conscience & freedom

    April 29, 2020 at 6:12 pm

    No wonder why China and WHO tag team against Remdesivir.

    • BiketripsETC

      April 29, 2020 at 6:44 pm

      @samsung a10 The study went for too long. They claim the drug is more effective in shorter duration.

    • Jason Crelopia

      April 29, 2020 at 10:05 pm

      Never trust any data coming out from China, GDP, number of infected and death, you name it

    • sparkle sparkles

      April 29, 2020 at 10:10 pm

      @Jason Crelopia why?

    • darlene harris

      April 30, 2020 at 12:38 am

      @sparkle sparkles like #LiarInChief … China lies, lies, lies, lies, lies …..

    • sparkle sparkles

      April 30, 2020 at 1:00 am

      @darlene harris You are gonna trust the people that said Iraq was hiding wmd? People that sacked Libya? People that dumped carcinogens into drinking water? What proof?

  2. samsung a10

    April 29, 2020 at 6:33 pm

    *TOTAL BS*
    I quote this China funded study:
    “In this study of adult patients admitted to hospital for severe COVID-19, remdesivir *was not* associated with statistically significant clinical benefits”
    (20)31022-9/fulltext

  3. Karla Smith

    April 29, 2020 at 6:39 pm

    Fauci is a liar! He’s been allowed to lie and dismantle our economy! Watch this video and share!

  4. BiketripsETC

    April 29, 2020 at 6:41 pm

    Dr. Fauci would make a great president. Too bad he is too smart for the job.

  5. A N

    April 29, 2020 at 6:49 pm

    He is SUCH a douche bag! So he has all the confidence in the world in a new drug that his buddies in big pharma benefit from but he has no confidence in drugs that have been in use for decades. You know why? The old drugs are not patented so his buddies will make NO money from them. Look at the other drugs this guys has pushed in the past, they were later taken off market because they killed MILLIONS. FUCK FAUCI

  6. Marla Holt

    April 29, 2020 at 6:50 pm

    This is working with Bill Gates to make money and that is all .ck his past and ck outthe utube video with DR SHIVA AND THE LETTER HE WROTE TO TRUMP ABOUTTHIS MAN.

  7. Dexter Morgan

    April 29, 2020 at 7:18 pm

    This is why Japan approved it two days ago

  8. Morgan Dexter

    April 29, 2020 at 7:56 pm

    Nice

  9. koti

    April 29, 2020 at 9:05 pm

    Basically drug is not much beneficial. They are trying to help in stock market.

  10. Owens Rayfeilds

    April 29, 2020 at 9:07 pm

    mr faucet ,,you know less than ,,the president,,,fix your voice,,you are sick,,,grey and blind,,,you are blind,,you are sick,,go to the hospital,,,how can we listen to a sick person,,,,
    maybe you have worms in your brain eating your cells,,,,you know nothing

  11. Pink Back Program Pink Back Program Vote

    April 29, 2020 at 9:47 pm

    Time will tell

  12. Ken Yup

    April 29, 2020 at 10:13 pm

    Glad to hear this good news

  13. Walter Duranty

    April 29, 2020 at 11:09 pm

    He has stock in Gilead since Dec 2019 at least!

  14. Lenira Susana

    April 29, 2020 at 11:57 pm

    these old people need to retire!

  15. crashoppe

    April 30, 2020 at 12:10 am

    do ppl actually still listen to this guy??? my immune system works just fine.

  16. The Misadventures of Jim

    April 30, 2020 at 12:19 am

    Interesting development, but I guess I’m not surprised.

    As that was unfolding since late February, they refused to fund HDCQ studies. (only 3 out of several hundred trials). The enrollment / admissions guidelines for 2 of those trials were so narrow they almost ensured you can’t use HDCQ on active patients this side of a ventilator and one is a prophylaxis exposure study.

    The Patented US made exotic only discovered in 2016 wins out over a 40 year old worldwide generic that has already proven effective, so much so it was included in S. Koreas clinical treatment guidelines published Feb 12th.

    You may remember that S. Korea, who is a world leader in biomedical research, snuffed their Covid issue out some time ago.

    Oh, and it’s an IV drug, so you have to be admitted to the floor for a 10 day course of treatment. $$$$

    Gilead’s stock sky rockets. Why am I not surprised?

    • darlene harris

      April 30, 2020 at 12:35 am

      go take your damn negativity elsewhere … thank the god that you are not awaiting this trial … oooh, wait … you still have time to be exposed, succumb …. too late!!!

    • The Misadventures of Jim

      April 30, 2020 at 1:08 am

      @darlene harris I would submit that I didn’t make myself entirely clear.

      Remdesivir will be fine once you are hospitalized. Under current protocols you will be very, very sick by the time that happens and even if you survive there is increasing evidence that this virus leaves you with permanent pulmonary damage.

      In the system that I work we are trying to prevent hospitalizations….which was the whole point of a nationwide lock down, flatten the curve to prevent the hospitals being overrun.

      Where I am I have been pushing for the community paramedicine option where we push out into the community, where people are sick in their homes, before they require hospitalization. We arrive, we test, we prescribe the zinc ionophores, we monitor via telemedicine.

      We intervene early in the disease process, we keep people out of the hospital….which is the approach that was successfully implemented in S. Korea.

  17. Joseph Swift

    April 30, 2020 at 1:10 am

  18. gmwizz

    April 30, 2020 at 1:26 am

    Glad trump didn’t open his GOB

Leave a Reply

Your email address will not be published. Required fields are marked *

Bloomberg Technology

President Trump Announces Apple and Intel Chip Collaboration | Bloomberg Tech 6/18/2026

Bloomberg’s Ed Ludlow discusses the latest announcement made by President Donald Trump, which will see Apple and Intel joining forces to produce chips domestically, sending shares of the chipmaker higher. Plus, Anduril’s CEO discusses how the company won a contract with the US Air Force to produce autonomous fighters. And, SpaceX wraps up its first…

Published

on

Bloomberg’s Ed Ludlow discusses the latest announcement made by President Donald Trump, which will see Apple and Intel joining forces to produce chips domestically, sending shares of the chipmaker higher. Plus, Anduril’s CEO discusses how the company won a contract with the US Air Force to produce autonomous fighters. And, SpaceX wraps up its first full week of trading, with shares falling for a second day straight.

Chapters:
00:00:00 – Bloomberg Tech Begins
00:01:12 – Ian King & Mandeep Singh, Bloomberg News
00:05:57 – Ankur Crawford, Alger
00:12:15 – Brian Schimpf, Anduril
00:20:57 – Matt Day, Bloomberg News
00:23:48 – Michael Regan, Bloomberg News
00:25:56 – Matthew Witheiler, Wellington Management
00:32:23 – Chris Pavolvski, Rumble CEO
00:37:18 – Dana Wollam, Bloomberg News
00:39:49 – Felix Gillette, Bloomberg News
00:41:42 – Randall Williams, Bloomberg News
——–
“Bloomberg Technology” is our daily news program focused exclusively on technology, innovation and the future of business hosted by Ed Ludlow from San Francisco and Caroline Hyde in New York.

Like this video? Subscribe and turn on the notifications for Bloomberg Technology on YouTube:

Watch the latest full episodes of “Bloomberg Technology” with Caroline Hyde and Ed Ludlow here:

Get the latest in tech from Silicon Valley and around the world here:

Follow Ed Ludlow on Twitter here:
Follow Caroline Hyde on Twitter here:

Connect with us on…
Twitter:
Facebook:
Instagram:

Continue Reading

Bloomberg Technology

Rumble Bets on AI Compute Demand With New AI Platform

Video platform Rumble is jumping on the AI bandwagon with its newest AI platform. Launching as Quake AI, the new sector combines cloud, compute, and AI infrastructure, and is slated to dominate the company’s business segment. Rumble CEO Chris Pavlovski joins Ed Ludlow on “Bloomberg Tech” with more on the pivot. ——– Like this video?…

Published

on

Video platform Rumble is jumping on the AI bandwagon with its newest AI platform. Launching as Quake AI, the new sector combines cloud, compute, and AI infrastructure, and is slated to dominate the company’s business segment. Rumble CEO Chris Pavlovski joins Ed Ludlow on “Bloomberg Tech” with more on the pivot.
——–
Like this video? Subscribe to Bloomberg Technology on YouTube:

 
Watch the latest full episodes of “Bloomberg Technology” with Caroline Hyde and Ed Ludlow here:

 
Get the latest in tech from Silicon Valley and around the world here:

Connect with us on…
X:
Facebook:
Instagram:
 
Follow Ed Ludlow on X here:
Follow Caroline Hyde on X here:
 
Listen to the daily Bloomberg Technology podcast here:

 
More from Bloomberg Business
Connect with us on…
X:
Facebook:
Instagram:
LinkedIn:
TikTok:

Continue Reading

Bloomberg Technology

Investors Anticipate Fresh Liquidity Following Historic SpaceX Debut

SpaceX’s historic public debut comes during a critical inflection point as a wave of multibillion-dollar AI companies prepare to go public. With the unprecedented IPO, investors are anticipating a wide-scale “distribution event” that will give private markets the fresh cash it desperately needs. Matt Witheiler, Head of Late-Stage Growth at Wellington Management, thinks the private…

Published

on

SpaceX’s historic public debut comes during a critical inflection point as a wave of multibillion-dollar AI companies prepare to go public. With the unprecedented IPO, investors are anticipating a wide-scale “distribution event” that will give private markets the fresh cash it desperately needs. Matt Witheiler, Head of Late-Stage Growth at Wellington Management, thinks the private tech ecosystem will see a cash return. He joins Ed Ludlow of “Bloomberg Tech”.
——–
Like this video? Subscribe to Bloomberg Technology on YouTube:

 
Watch the latest full episodes of “Bloomberg Technology” with Caroline Hyde and Ed Ludlow here:

 
Get the latest in tech from Silicon Valley and around the world here:

Connect with us on…
X:
Facebook:
Instagram:
 
Follow Ed Ludlow on X here:
Follow Caroline Hyde on X here:
 
Listen to the daily Bloomberg Technology podcast here:

 
More from Bloomberg Business
Connect with us on…
X:
Facebook:
Instagram:
LinkedIn:
TikTok:

Continue Reading

Trending